Clinical Trials Logo

Organophosphate Poisoning clinical trials

View clinical trials related to Organophosphate Poisoning.

Filter by:

NCT ID: NCT02040350 Completed - Deaths Clinical Trials

Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?

Start date: April 2012
Phase: Phase 1
Study type: Interventional

To evaluate the effectiveness of Pralidoxime, a drug used for treatment of pesticide poisoning (Organophosphorous poisonings)

NCT ID: NCT00947596 Completed - Clinical trials for Organophosphorus Poisoning

A Study of Inhaled Atropine Sulfate in Healthy Adults

Start date: August 2009
Phase: Phase 1
Study type: Interventional

MicroDose Defense Products, LLC is developing an atropine dry powder inhaler (ADPI). This pilot study compares the pharmacokinetics (PK) of inhaled dry powder atropine as delivered by the ADPI to atropine delivery from the AtroPen autoinjector.

NCT ID: NCT00389259 Withdrawn - Clinical trials for Neurotoxicity Syndromes

Scopolamine Treatment for Patients With Organophosphate Poisoning

Start date: October 2007
Phase: N/A
Study type: Interventional

Organophosphate (OP) compounds are a major threat as chemical warfare agents or in terrorist act. OPs are also the active ingredient of many insecticides. Ingestion of insecticides is a common cause of death among people who commit suicide in developing countries. OPs poisoning also frequently occurs after accidental exposure to agricultural OPs and in children as a result of unintentional ingestion. The use of competitive inhibitors of acetylcholine other than atropine for patient with organophosphate (OP) poisoning is controversial. Because scopolamines' ability to cross the blood brain barrier is better than atropine, it has been suggested that scopolamine should be used OP poisoned patients who have central nervous system (CNS) manifestations. However there is controversy regarding its potential benefit in the treatment of organophosphate poisoning in humans. To the best of our knowledge there are no randomised controlled studies on the use of scopolamine in humans. This prospective randomised controlled study is aimed to determine whether adding scopolamine to the standard treatment of atropine and oximes in patients with CNS symptoms of OP poisoning improve the outcome.